MaxCyte Inc (MXCT)
MaxCyte, Inc. is a U.S.-based life sciences company focused on developing and commercializing cell therapeutics. The company’s portfolio includes the ExPERT platform, a set of electroporation instruments designed for different stages and scales of cell engineering. ExPERT ATx is used for small to medium-scale transfection, ExPERT STx supports protein production, drug development, and therapeutic target expression for cell-based assays, ExPERT GTx is aimed at large-scale therapeutic applications, and ExPERT VLx is designed for very large-volume cell engineering. MaxCyte also supplies disposable processing assemblies and related accessories, including electroporation buffer solutions and software protocols. The company licenses and sells its instruments and technology, and sells consumables to cell therapy developers, pharmaceutical companies, and biotechnology companies for applications in drug discovery, development, and biomanufacturing. Founded in 1998, MaxCyte is headquartered in Rockville, Maryland, and its common stock is listed on NASDAQ under the symbol MXCT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MXCT
|
$1.48
|
22.1% Upside
|
Undervalued
|
$4.11
|
238.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-3.3x
|
0.8x
|
4.0x
|
125.3 M
|
40.786 M
|
12.2%
|
91.1%
|
1.1
|
—
|
75.0%
|
